Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Accumulated Depreciation: 2020-2023

Historic Accumulated Depreciation for Relay Therapeutics (RLAY) over the last 4 years, with Dec 2023 value amounting to $23.6 million.

  • Relay Therapeutics' Accumulated Depreciation rose 28.24% to $23.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was $23.6 million, marking a year-over-year increase of 28.24%. This contributed to the annual value of $23.6 million for FY2023, which is 28.24% up from last year.
  • Latest data reveals that Relay Therapeutics reported Accumulated Depreciation of $23.6 million as of FY2023, which was up 28.24% from $18.4 million recorded in FY2022.
  • Over the past 5 years, Relay Therapeutics' Accumulated Depreciation peaked at $23.6 million during FY2023, and registered a low of $10.5 million during FY2020.
  • In the last 3 years, Relay Therapeutics' Accumulated Depreciation had a median value of $18.4 million in 2022 and averaged $18.8 million.
  • Data for Relay Therapeutics' Accumulated Depreciation shows a peak YoY skyrocketed of 36.44% (in 2021) over the last 5 years.
  • Relay Therapeutics' Accumulated Depreciation (Yearly) stood at $10.5 million in 2020, then spiked by 36.44% to $14.4 million in 2021, then increased by 27.99% to $18.4 million in 2022, then climbed by 28.24% to $23.6 million in 2023.